A North American population’s predictors of early clopidogrel discontinuation after drug-eluting stent implantation




Background


The association between early discontinuation of clopidogrel after drug-eluting stent (DES) implantation and an increased risk of adverse cardiovascular events is well documented. However, little is known about the prevalence and predictors of premature discontinuation at this time; therefore we sought to evaluate them in our population.




Methods


Patients who underwent DES implantation and were discharged on dual antiplatelet therapy (DAPT) were divided into two groups whether or not they discontinued prematurely the clopidogrel. We collected and compared their demographic and baseline data.




Methods


Patients who underwent DES implantation and were discharged on dual antiplatelet therapy (DAPT) were divided into two groups whether or not they discontinued prematurely the clopidogrel. We collected and compared their demographic and baseline data.

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Coronary stenting with MGuard: extended follow-up of first human trial
  2. Economic modeling of new stent platforms to evaluate cost effectiveness: analysis of the TAXUS Liberté vs. TAXUS Express stents in small vessel coronary stenting
  3. Treatment of STEMI with neither PCI nor thrombolysis
  4. Definite stent thrombosis: a 2-center New Zealand registry

Stay updated, free articles. Join our Telegram channel
Tags:
Nov 16, 2017 | Posted by in CARDIOLOGY | Comments Off on A North American population’s predictors of early clopidogrel discontinuation after drug-eluting stent implantation

Full access? Get Clinical Tree
Get Clinical Tree app for offline access